CSL's VarmX deal opens new R&D focus, says Jefferies

** Jefferies believes Australia's CSL CSL and the global plasma industry have potential to continue strong growth as expansion in blood-collection centres, inventory and capacity in line with demand

** Says CSL's new agreement with Dutch private firm VarmX is "evidence" for the biotech major's renewed focus on research and development (R&D) by buying assets into its pipeline

** CSL on Tuesday said that it will pay $117 million upfront to VarmX for an exclusive option to acquire the firm and advance the development of VMX-C001 blood coagulation therapy

** Jefferies estimates annual peak sales for VMX-C001 at $240 million

** Says while co's efforts to "re-energise" its research function will likely take time, the deal could help with speciality product growth in the medium term

** Stock down 28.3% so far this year as of last close, lagging behind a 15% decline on the ASX Healthcare index XHJ